BWX Technologies, Inc. - BWXT STOCK NEWS

BWX Technologies, Inc. (BWXT) reported Q4 2022 diluted GAAP EPS of $0.47, down 63% from $1.26 a year ago, with revenue of $624.2 million, a 5% increase year-over-year. For the full year, GAAP EPS decreased by 20% to $2.60, while adjusted EBITDA rose to $439.4 million. Operating cash flow for 2022 was $244.7 million. The company declared a quarterly cash dividend increase to $0.23 per share, payable on March 28, 2023. Despite solid results, labor market challenges are expected to hinder growth in 2023. BWXT's 2023 guidance estimates revenue of ~$2.4 billion and adjusted EBITDA of ~$475 million.

Ontario Power Generation's Darlington Nuclear Generating Station has successfully installed a new isotope system, enabling the production of life-saving Molybdenum-99 (Mo-99) isotopes, a first for a commercial reactor. This innovative production will help alleviate the long-standing shortages of Mo-99, crucial for generating Technetium-99m, a primary diagnostic imaging agent in nuclear medicine. The project, a collaboration between Laurentis Energy Partners and BWXT Medical Ltd., awaits final regulatory approvals from the FDA and Health Canada before commercial production begins. The facility can produce enough Mo-99 to meet a significant portion of North America's demand.

BWX Technologies, Inc. (NYSE: BWXT) will release its fourth quarter and full-year 2022 results on February 23, 2023, post-market. A conference call is scheduled for 5:00 p.m. EST, enabling listeners to join and view the presentation online. BWXT is headquartered in Lynchburg, Virginia, and is recognized as a leading innovator in nuclear solutions, serving sectors including global security and clean energy. The company has approximately 6,700 employees and operates major sites throughout the U.S., Canada, and the U.K., contributing to its critical roles in projects for the U.S. Department of Energy and NASA.

Fusion Pharmaceuticals Inc. and BWXT Medical have announced a preferred partner agreement for the supply of actinium-225, vital for targeted alpha therapies. This agreement ensures Fusion's access to high-purity actinium needed for its expanding clinical pipeline, which includes three proprietary programs in trials. BWXT Medical, a leader in medical isotopes, will provide actinium at volume-based pricing, enhancing Fusion's supply chain and supporting future growth. The collaboration aims to meet the growing demand for effective cancer treatments utilizing alpha-emitting isotopes.

Fusion Pharmaceuticals and BWXT Medical have established a preferred partner agreement for the supply of actinium-225, enhancing Fusion's existing isotope supply for its clinical-stage radiopharmaceuticals. This strategic partnership is poised to support growing demand for targeted alpha therapies (TATs) while ensuring volume-based pricing. The collaboration emphasizes BWXT's commitment to meeting the global actinium supply needs, bolstering Fusion's clinical programs and future business opportunities.

BWX Technologies, Inc. (NYSE: BWXT) announced the promotion of Ronald O. (Chip) Whitford, Jr. to senior vice president, general counsel, and chief compliance officer, effective January 2, 2023. He succeeds Thomas E. McCabe, who will transition to a special advisor role until his retirement on August 1, 2023. Whitford, with a background in legal affairs spanning multiple industries, has been with BWXT since 2017. This move is part of the company’s succession planning strategy, ensuring continuity in its legal and compliance functions.

BWX Technologies (NYSE: BWXT) has marked a significant breakthrough with the production of TRISO nuclear fuel, celebrated alongside officials from the U.S. Department of Defense, Department of Energy, NASA, and Idaho National Laboratory. This fuel, noted for its robustness, will power the first U.S. microreactor under Project Pele with a $37 million grant from Idaho National Laboratory. BWXT aims to enhance energy resilience, enabling clean energy objectives and support for military and disaster responses.

BWX Technologies reported a strong third quarter 2022, with revenue of $523.7 million and a net income of $61.8 million or $0.67 EPS. The commercial operations segment grew by 22%, while overall revenue increased by 5% compared to the previous year. Adjusted EBITDA stood at $100.1 million. The company has narrowed its 2022 earnings guidance but anticipates revenue and EBITDA growth in 2023, supported by key nuclear projects and FDA acceptance of its technetium-99m generator application for priority review.

BWX Technologies, Inc. (NYSE: BWXT) announced participation in three investor conferences before year-end. Key events include:

• Nov. 9: Baird Global Industrial Conference, Chicago.
• Dec. 1: Credit Suisse 10th Annual Global Industrial Conference, Manalapan, Florida.
• Dec. 6: Truist Securities Industrials and Services Summit, New York City.

Executives attending include CEO Rex Geveden, CFO Robb LeMasters, and VP of Investor Relations Mark Kratz. For further details about BWXT, visit their website.